Nearly a year ago, Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss drug ...

Viking isn't generating consistent revenue today but it could have a blockbuster drug on its hands in VK2735. The weight loss candidate begins phase 3 trials this year, and positive results could help ...

Shares of Viking Therapeutics have fallen by more than half since the stock peaked early last year. Viking Therapeutics is developing a drug that might be able to outperform today's most popular ...